Maat Pharma SA
PAR:MAAT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
ROPEOK Technology Group Co Ltd
SSE:688619
|
CN |
Maat Pharma SA
Operating Expenses
Maat Pharma SA
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Maat Pharma SA
PAR:MAAT
|
Operating Expenses
-€32.9m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Operating Expenses
-€149.1m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-11%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Operating Expenses
-€122.2m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-20%
|
|
|
Inventiva SA
PAR:IVA
|
Operating Expenses
-€145.5m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Operating Expenses
-$151.8m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-11%
|
|
|
Abivax SA
PAR:ABVX
|
Operating Expenses
-€246.1m
|
CAGR 3-Years
-69%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
-30%
|
|
Maat Pharma SA
Glance View
Maat Pharma SA operates as a clinical-stage microbiome therapeutics company. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 43 full-time employees. The company went IPO on 2021-11-08. The firm specializes in the microbiome therapy that is aimed to treatment of Gut Microbiota alteration (Dysbiosis) using patient-specific biotherapeutics in patients with serious medical conditions. Its MaaT Microbiome Restoration Therapy (MMRB) discovery and analysis platform supports the evaluation of drug candidates, the determination of new disease targets and the identification of biomarkers for microbiome-related conditions.
See Also
What is Maat Pharma SA's Operating Expenses?
Operating Expenses
-32.9m
EUR
Based on the financial report for Dec 31, 2025, Maat Pharma SA's Operating Expenses amounts to -32.9m EUR.
What is Maat Pharma SA's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-44%
Over the last year, the Operating Expenses growth was -8%. The average annual Operating Expenses growth rates for Maat Pharma SA have been -31% over the past three years , -44% over the past five years .
